H. David Ulmert

H. David Ulmert is a Researcher in the Department of Pharmacology at the University of California, Los Angeles (UCLA). He previously held positions at Memorial Sloan Kettering Cancer Center (Research Fellow, 2014) and Sloan Kettering Institute (Senior Research Scientist, 2018), focusing on Nuclear Medicine and Pharmacology.

• MD (2006) and PhD (2007) from Lund University
• Internship in Surgery/Medicine (2008) at Helsingborg County Hospital
• Residency in Surgery (2008) at Skåne University Hospital

His research centers on advancing PET imaging and radioimmunotherapy by targeting secreted antigens via FcRn trafficking. This innovation enables intracellular delivery of radiotherapeutics to prostate and breast carcinomas, leveraging circulating biomarkers like hK2 and PSA. He co-founded a biotech startup to humanize and produce the hK2-targeting antibody, culminating in a phase 1 clinical trial (NCT04116164) with a major pharmaceutical company.

He has conducted population-based clinical studies to identify risk factors and biomarkers for prostate cancer, collaborating with experts to publish paradigm-shifting work on kallikreins. His lab at UCLA Health (23-360B CHS) currently includes graduate student Claire Storey.

His work integrates oncology, molecular biology, and pharmacology, with a focus on improving cancer diagnostics and therapeutics.

Collaborations include Memorial Sloan Kettering Cancer Center, Skåne University Hospital, and UCLA Health. His clinical trial (NCT04116164) demonstrates translational partnerships with pharmaceutical companies.